Phospho-SOX9 (S181) Antibody

What is the specificity of Phospho-SOX9 (S181) antibody?

The Phospho-SOX9 (S181) polyclonal antibody demonstrates high specificity for detecting endogenous levels of SOX9 protein exclusively when phosphorylated at serine 181. This antibody does not cross-react with non-phosphorylated SOX9 or SOX9 phosphorylated at other sites. The specificity has been validated through multiple experimental approaches including the use of phosphorylation-deficient mutants (S181A) in which no signal is detected . The antibody was generated using a synthetic phosphopeptide derived from human SOX9 surrounding the phosphorylation site of serine 181 .

What is the biological significance of SOX9 phosphorylation at S181?

SOX9 phosphorylation at S181 serves as a critical post-translational modification with multiple functional consequences:

• Transcriptional Activity Enhancement: Phosphorylation at S181 significantly increases SOX9's transcriptional activity on target genes. Studies have shown that PTHrP-induced phosphorylation of SOX9 at S181 increases its activity on chondrocyte-specific enhancers in the type II collagen (Col2a1) gene . This enhanced activity was abolished in Sox9 mutants with serine-to-alanine substitutions at the PKA phosphorylation sites.

• Growth Plate Regulation: In the growth plate of endochondral bones, SOX9 phosphorylated at S181 is detected almost exclusively in chondrocytes of the prehypertrophic zone, where it helps maintain the chondrocyte phenotype and inhibits maturation to hypertrophic chondrocytes . This phosphorylation is dependent on PTHrP signaling, as demonstrated by its absence in PTH/PTHrP receptor null mutant mice.

• Neural Crest Development: Phosphorylation of SOX9 at S181 is required for neural crest delamination. In chicken embryos, phosphorylated SOX9 was detected in premigratory and emigrating neural crest cells but not in dorsal neural folds . Mutation studies showed that phosphorylation of SOX9 is essential for neural crest migration.

• Oncogenic Signaling: In pancreatic cancer models, SOX9 phosphorylation at S181 is induced by oncogenic Kras signaling, suggesting a role in cancer progression .

Which signaling pathways regulate SOX9 phosphorylation at S181?

Several signaling pathways have been identified that regulate SOX9 phosphorylation at S181:

• PTHrP-PKA Pathway: Parathyroid hormone-related peptide (PTHrP) strongly increases SOX9 phosphorylation at S181 through protein kinase A (PKA). This phosphorylation is blocked by H89, a PKA-specific inhibitor, but not by OA, a phosphatase inhibitor . This pathway is particularly important in chondrocyte development.

• AKT Signaling: AKT can directly phosphorylate SOX9 at S181 in vitro. In mammary tumor cells, inhibition of AKT blocks Sox9 phosphorylation and subsequent Sox10 expression. This mechanism appears important in breast cancer development, as analysis of murine and human mammary tumors reveals a direct correlation between phospho-Sox9 S181 levels and Sox10 expression .

• Oncogenic Kras: In pancreatic cells, oncogenic Kras promotes phosphorylation of SOX9 at S181. Western blot assays confirmed that SOX9-p S181 expression levels were elevated in Kras-transformed pancreatic cell lines (HPNE/Kras and HPDE/Kras) compared to their parental lines .

• NF-κB Pathway: Evidence suggests that the NF-κB pathway may indirectly regulate SOX9 phosphorylation. In pancreatic cancer cells, inhibition of NF-κB through expression of a phosphorylation-defective IκBα mutant resulted in downregulation of SOX9 expression .

What are the optimal protocols for detecting Phospho-SOX9 (S181) in different tissue types?

Optimal detection of Phospho-SOX9 (S181) varies by tissue type and application:

For Paraffin-Embedded Human Tissues (IHC):

• Deparaffinize sections and perform antigen retrieval in 10mM citrate buffer (pH 6.0)

• Quench with 3% hydrogen peroxide

• Block in 5% donkey serum

• Incubate overnight with Phospho-SOX9 (S181) antibody at 1:50 dilution at 4°C

• Wash sections and incubate with appropriate HRP-conjugated secondary antibody

• Develop using DAB substrate and counterstain with hematoxylin

This protocol has been successfully used for human colon carcinoma tissue, showing specific nuclear staining of phosphorylated SOX9. For negative controls, PBS should be used instead of primary antibody .

For Mouse/Rat Tissues:
When using mouse monoclonal antibodies on mouse tissues, add a mouse-on-mouse blocking solution (Vector Laboratories) to the blocking step to reduce background . This is particularly important for growth plate tissue sections where phospho-SOX9 expression is highly specific to the prehypertrophic zone .

For Neural Tissue and Embryonic Sections:
Immunofluorescence on transverse sections of chicken embryos (Hamburger and Hamilton stage 12) successfully detected phosphorylated SOX9 in premigratory and emigrating neural crest cells .

How should Western blot experiments be optimized for Phospho-SOX9 (S181) detection?

For optimal Western blot detection of Phospho-SOX9 (S181):

• Sample Preparation:

  • For cell lines: Treat HeLa cells with PMA (100nM, 30min) to induce phosphorylation

  • For tissue samples: Fresh extraction from mouse brain or rat liver provides good signals

  • Use phosphatase inhibitors in lysis buffers to preserve phosphorylation status

• Running Conditions:

  • Use 10% SDS-PAGE gels

  • Look for a band at approximately 56 kDa

• Antibody Dilution and Incubation:

  • Recommended dilution: 1:500

  • Primary antibody incubation: Overnight at 4°C

  • Secondary antibody: HRP-conjugated anti-rabbit IgG

• Controls:

  • Positive control: Samples treated with PKA activators or PTHrP

  • Negative control: Samples treated with PKA inhibitor H89

  • Specificity control: SOX9 S181A mutant-expressing cells

• Signal Enhancement:

  • For weak signals, consider using a more sensitive ECL substrate

  • Avoid repeated freeze-thaw cycles of the antibody which may reduce sensitivity

How can chromatin immunoprecipitation (ChIP) be performed using Phospho-SOX9 (S181) antibody?

For successful ChIP experiments with Phospho-SOX9 (S181) antibody:

• Cell Preparation:

  • Seed 6 million cells per condition in two 15-cm plates and culture for 48 hours

  • Cross-link cells in 1% formaldehyde for 10 minutes at room temperature

  • Quench formaldehyde with glycine (final concentration 125 mM)

• Chromatin Preparation:

  • Extract nuclei, digest chromatin, and prepare for immunoprecipitation using a commercial ChIP kit (e.g., SimpleChip Kit from Cell Signaling Technologies)

  • Include a pre-clearing step with beads alone prior to immunoprecipitation

• Immunoprecipitation:

  • Use 10 μg of chromatin per immunoprecipitation

  • Add 1 μg of Phospho-SOX9 (S181) antibody

  • Include appropriate controls (IgG, non-phospho SOX9 antibody)

• DNA Recovery and Analysis:

  • After ChIP and DNA cleanup, analyze by qPCR

  • For qPCR: Mix 6.5 μL of chromatin with 35 μL of SYBR Green Supermix, 6.5 μL of primers (5μM), and 21 μL of nuclease-free water

This protocol has been validated for identifying Sox9 binding to SoxE sites in the Sox10 -7kb enhancer region, demonstrating that phosphorylated Sox9 binds to regulatory elements of target genes .

How does Phospho-SOX9 (S181) interact with SUMOylation in regulating SOX9 function?

The relationship between SOX9 phosphorylation and SUMOylation represents a complex regulatory mechanism:

• Hierarchical Regulation: Phosphorylation of either S64 or S181 is required for SOX9 SUMOylation, but phosphorylation is not dependent on SUMOylation. Experimental evidence shows that wild-type SOX9 and single phospho-mutant SOX9 are efficiently SUMOylated, but SUMOylation is completely abolished in the SOX9 S64A,S181A double mutant .

• Functional Consequences: In neural crest development, both modifications work in concert to regulate proper neural crest delamination. The non-SUMOylatable form of SOX9 can still be phosphorylated at S181, but fails to support neural crest migration, indicating that both modifications are required for this developmental process .

• Experimental Detection: The presence of both modifications can be detected using specific antibodies against phosphorylated SOX9 and using SUMOylation assays. The functional interplay can be demonstrated using phosphorylation-deficient mutants (S64A,S181A) and constitutively active protein kinase A (CA-PKA) .

What is the relationship between PTHrP signaling and SOX9 phosphorylation in the growth plate?

The relationship between PTHrP signaling and SOX9 phosphorylation in the growth plate has been well-characterized:

• Spatial Correlation: SOX9 phosphorylated at S181 is detected almost exclusively in the prehypertrophic zone of the growth plate, which overlaps with the major site of expression of the PTH/PTHrP receptor .

• Genetic Evidence: In PTH/PTHrP receptor null mutant mice, SOX9 phosphorylation at S181 is completely absent in the prehypertrophic zone, while the general distribution of total SOX9 remains unchanged. This provides compelling evidence that PTHrP signaling is required for SOX9 phosphorylation in vivo .

• Mechanistic Pathway: PTHrP binding to its receptor activates PKA, which directly phosphorylates SOX9 at S181. This phosphorylation increases SOX9's transcriptional activity on chondrocyte-specific genes like Col2a1 .

• Functional Outcome: Phosphorylated SOX9 helps maintain the chondrocyte phenotype of cells in the prehypertrophic zone and inhibits their maturation to hypertrophic chondrocytes, thus regulating the rate of chondrocyte maturation in the growth plate .

What is the role of Phospho-SOX9 (S181) in cancer progression?

Emerging evidence suggests important roles for Phospho-SOX9 (S181) in cancer:

• Pancreatic Cancer: In pancreatic ductal adenocarcinoma (PDAC) models, oncogenic Kras promotes nuclear translocation of SOX9 and enhances expression of phosphorylated SOX9. Western blot assays confirmed that SOX9-p S181 expression levels were elevated in Kras-transformed pancreatic cell lines (HPNE/Kras and HPDE/Kras) . This suggests phosphorylated SOX9 might be gradually functionally activated in the progression from acinar-ductal metaplasia (ADM) to pancreatic intraepithelial neoplasias (PanINs) and ultimately PDAC.

• Breast Cancer: AKT-mediated phosphorylation of Sox9 at S181 induces Sox10 transcription in mammary tumor cells. Analysis of murine and human mammary tumors reveals a direct correlation between phospho-Sox9 S181 levels and Sox10 expression. Genetic deletion of SLK (STE20-like kinase) results in Sox10 induction and significantly accelerates tumor initiation in HER2-induced mammary tumors, with AKT-mediated Sox9 phosphorylation as the underlying mechanism .

• Melanoma: SOX9 and phosphorylated SOX9 expressions are increased after UVB exposure in melanocytes, suggesting a role in UVB-induced melanocyte differentiation or transformation. This phosphorylation can be prevented by pretreatment with the PKA inhibitor H89 .

• Expression in Cancer Tissues: Immunohistochemistry analyses show nuclear staining of phosphorylated SOX9 in human colon carcinoma tissue , suggesting its potential utility as a biomarker or therapeutic target.

What are common issues with Phospho-SOX9 (S181) antibody staining and how can they be resolved?

Researchers may encounter several challenges when using Phospho-SOX9 (S181) antibody:

• High Background in IHC/IF:

  • Problem: Non-specific staining throughout tissue sections

  • Solution: Increase blocking time (use 5% donkey serum or BSA for at least 1 hour), optimize antibody dilution (start with 1:100 and titrate), and include additional washing steps with 0.1% Tween-20 in PBS

• Weak or No Signal:

  • Problem: Inability to detect phosphorylated SOX9 despite known expression

  • Solution: Ensure proper antigen retrieval (10mM citrate buffer, pH 6.0), verify that phosphorylation state is preserved during sample preparation by using phosphatase inhibitors, and consider signal amplification methods

• Cytoplasmic Instead of Nuclear Staining:

  • Problem: Unexpected cytoplasmic localization when nuclear staining is expected

  • Solution: Verify fixation protocol (over-fixation can prevent nuclear antigen detection), optimize permeabilization, and ensure proper handling of samples to prevent protein translocation during processing

• Cross-Reactivity Issues:

  • Problem: Antibody detecting non-specific proteins

  • Solution: Include appropriate controls (phospho-deficient mutant S181A, competition with immunizing peptide), and increase antibody dilution

• Storage-Related Loss of Activity:

  • Problem: Decreased sensitivity after storage

  • Solution: Avoid repeated freeze-thaw cycles, store at -20°C or -80°C in small aliquots, and use fresh dilutions for each experiment

How should experimental controls be designed for validating Phospho-SOX9 (S181) antibody specificity?

Proper experimental controls are crucial for validating the specificity of Phospho-SOX9 (S181) antibody:

• Positive Controls:

  • Cell lines treated with PKA activators (e.g., forskolin) or PTHrP to induce SOX9 phosphorylation

  • HeLa cells treated with PMA (100nM, 30min) have been validated to show increased SOX9 phosphorylation

  • Prehypertrophic zone of wild-type growth plate tissue sections, which naturally express phosphorylated SOX9

• Negative Controls:

  • Pretreatment of samples with PKA inhibitor H89, which prevents SOX9 phosphorylation

  • PTH/PTHrP receptor null mutant mice tissues, which lack SOX9 phosphorylation in the growth plate

  • Primary antibody omission control (PBS instead of primary antibody)

• Specificity Controls:

  • Cells expressing SOX9 S181A mutant, which cannot be phosphorylated at this site

  • Peptide competition assay using the immunizing phosphopeptide

  • Dephosphorylation controls: treating lysates with lambda phosphatase before immunoblotting

• Expression Controls:

  • Parallel staining with antibodies against total SOX9 to confirm that the protein is expressed even when phosphorylation is absent

  • Comparison of phospho-SOX9 detection in tissues known to express high levels (growth plate) versus low levels (hypertrophic chondrocytes)

These controls have been validated in multiple studies and ensure that any observed signals truly represent phosphorylated SOX9 at S181 rather than artifacts or cross-reactivity.

What emerging applications of Phospho-SOX9 (S181) antibody show promise in translational research?

Several emerging applications of Phospho-SOX9 (S181) antibody show potential for translational research:

• Cancer Biomarker Development:

  • The correlation between phospho-Sox9 S181 levels and Sox10 expression in mammary tumors suggests potential use as a prognostic biomarker

  • In pancreatic cancer, phosphorylated SOX9 appears to be involved in oncogenic Kras signaling, potentially serving as a biomarker for early malignant transformation

• Developmental Biology Tools:

  • Tracking neural crest cell migration and differentiation during embryonic development

  • Monitoring chondrocyte maturation in cartilage development and repair

• Therapeutic Target Identification:

  • Screening compounds that inhibit SOX9 phosphorylation at S181 could identify candidates for cancer therapy

  • Evaluating PTHrP-PKA-SOX9 axis modulation for cartilage regeneration approaches

• Advanced Imaging Applications:

  • Development of proximity ligation assays to detect interaction between phosphorylated SOX9 and its cofactors in situ

  • Multiplexed imaging to simultaneously detect multiple phosphorylation sites and correlate with functional outcomes

These applications could eventually lead to new diagnostic tools and therapeutic approaches for conditions ranging from skeletal disorders to various cancers where SOX9 phosphorylation plays a role.

What are unresolved questions regarding the role of SOX9 phosphorylation at S181?

Despite significant advances, several key questions about SOX9 phosphorylation remain unanswered:

• Temporal Dynamics and Reversibility:

  • How quickly does S181 phosphorylation occur in response to various stimuli?

  • What phosphatases are responsible for dephosphorylating SOX9 at S181?

  • How do cycles of phosphorylation/dephosphorylation regulate SOX9 function?

• Interaction with Other Modifications:

  • Beyond SUMOylation, how does S181 phosphorylation interact with other post-translational modifications like acetylation or methylation?

  • Is there crosstalk between phosphorylation at S181 and other phosphorylation sites on SOX9?

• Differential Genomic Targeting:

  • Does phosphorylation at S181 alter the genomic binding profile of SOX9?

  • Are there target genes specifically regulated by phosphorylated SOX9 versus non-phosphorylated SOX9?

• Tissue-Specific Functions:

  • Why is phosphorylated SOX9 at S181 found predominantly in certain cell types like prehypertrophic chondrocytes?

  • Are there tissue-specific cofactors that interact specifically with phosphorylated SOX9?

• Therapeutic Potential:

  • Can selective inhibition of SOX9 phosphorylation at S181 be achieved without affecting other essential functions?

  • Would such inhibition be therapeutically beneficial in cancer contexts where phosphorylated SOX9 drives progression?